Pharmaceutical manufacturer 🇺🇸, United States
Eli Lilly develops and manufactures medicines for diabetes, obesity, cancer and other diseases. Its portfolio includes Mounjaro and Zepbound (tirzepatide) and Trulicity (dulaglutide). Its activity in this market spans medicine sales, investment in emerging drug developers and the development of new treatments.
As of 2026-09-14 · USD · Recorded monthly observations
Last 12 months
Last 12 months
Fierce Pharma reports that newly released agreement documents have prompted questions about how much Lilly’s US pricing deal will save on GLP-1 obesity medicines.
Eli LillyNovo Nordisk says its experimental CagriSema injection produced more weight loss than a tested dose of Lilly’s tirzepatide in adults with type 2 diabetes. The comparison does not cover every available dose.
Lilly says construction has begun on a $6.5 billion Houston factory to make ingredients for Foundayo and other medicines. The factory is intended to expand production capacity; it is not yet operating.
Eli LillyLilly has stopped work on the experimental obesity drug LY4064912, Fierce Biotech reported. The decision concerns an early research project, rather than Lilly’s approved weight-loss medicines.
Eli LillyFierce Pharma reported record weekly prescriptions for Novo’s Wegovy pill and Lilly’s Foundayo. The figures track prescriptions, including refills, rather than new patients or comparative treatment results.
Investors led by BVF Partners are providing Superluminal with $60 million to advance an experimental obesity treatment. Lilly is participating as an investor in this funding round.
Lilly reports one-year results from studies adding weight-loss drug Zepbound to Taltz, its treatment for psoriasis and psoriatic arthritis. The studies compared the combination with Taltz alone.
Eli LillyLilly says U.S. regulators have expanded Mounjaro’s approved uses to include reducing cardiovascular risks in high-risk adults with type 2 diabetes. Mounjaro was already approved for blood-sugar control.
Eli LillyLilly reports lower medical spending among older adults using its weight-loss injection Zepbound. The estimates exclude the medicine’s price and cannot establish that treatment caused the difference.
Eli LillyLilly says demand for Mounjaro and Zepbound helped lift quarterly sales to $23 billion. Both medicines contain tirzepatide, sold under different brands for diabetes and weight management.
Eli LillyLilly announced an expanded role for Daniel Skovronsky as chief scientific and product officer, overseeing research and development alongside launches and product strategy in cardiometabolic health, immunology and neuroscience. He continues to report to chair and CEO David Ricks.
Eli LillyGrow revenue at each location and build a commercial model that can scale across a clinic group.
Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.
SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.
SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.
All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.
